Evidence map›Paper›PMID 39494610›Full record

ArticleBriefings in bioinformatics2024

Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity.

Sébastien De Landtsheer, Apurva Badkas, Dagmar Kulms, Thomas Sauter

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sébastien De LandtsheerDepartment of Life Sciences and Medicine, University of Luxembourg, 2, place de l'Université, L4365 Esch-sur-Alzette, Luxembourg.
Apurva BadkasDepartment of Life Sciences and Medicine, University of Luxembourg, 2, place de l'Université, L4365 Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-4120-1963
Dagmar KulmsExperimental Dermatology, Department of Dermatology, Technische Universität-Dresden, 01307 Dresden, Germany.
Thomas SauterDepartment of Life Sciences and Medicine, University of Luxembourg, 2, place de l'Université, L4365 Esch-sur-Alzette, Luxembourg.ORCID 0000-0001-8225-2954

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stratification of patients diagnosed with cancer has become a major goal in personalized oncology. One important aspect is the accurate prediction of the response to various drugs. It is expected that the molecular characteristics of the cancer cells contain enough information to retrieve specific signatures, allowing for accurate predictions based solely on these multi-omic data. Ideally, these predictions should be explainable to clinicians, in order to be integrated in the patients care. We propose a machine-learning framework based on ensemble learning to integrate multi-omic data and predict sensitivity to an array of commonly used and experimental compounds, including chemotoxic compounds and targeted kinase inhibitors. We trained a set of classifiers on the different parts of our dataset to produce omic-specific signatures, then trained a random forest classifier on these signatures to predict drug responsiveness. We used the Cancer Cell Line Encyclopedia dataset, comprising multi-omic and drug sensitivity measurements for hundreds of cell lines, to build the predictive models, and validated the results using nested cross-validation. Our results show good performance for several compounds (Area under the Receiver-Operating Curve >79%) across the most frequent cancer types. Furthermore, the simplicity of our approach allows to examine which omic layers have a greater importance in the models and identify new putative markers of drug responsiveness. We propose several models based on small subsets of transcriptional markers with the potential to become useful tools in personalized oncology, paving the way for clinicians to use the molecular characteristics of the tumors to predict sensitivity to therapeutic compounds.

Indexed as

Machine LearningNeoplasmsAntineoplastic AgentsCell Line, TumorComputational BiologyHumansMultiomicsPrecision MedicineAntineoplastic AgentscancerCCLEmachine-learningpharmacosensitivitypredictive algorithm

Identifiers

PMID39494610
PMCPMC11532660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.